论文部分内容阅读
目的:观察和分析在原发性高血压的诊治过程中运用缬沙坦结合硝苯地平控释片的临床疗效情况。方法:按照患者自愿原则将我院内科在2014年04月~2015年04月期间,收治的77例原发性高血压患者进行分组治疗。即:对照组35例,给予常规方法治疗;观察组42例,给予缬沙坦联合硝苯地平控释片治疗。分析和对比两组患者的临床诊治情况和疗效。结果:经过临床治疗,观察组的临床诊治总有效率(97.62%)较之对照组患者(85.71%)显著偏高,比较具有统计学意义(P<0.05)。两组的不良反应率(4.76%,8.57%)均较低,且比较不存在统计学意义(P>0.05)。结论:给予原发性高血压患者缬沙坦联合硝苯地平控释片进行临床诊疗,其治疗效果选择,不良反应轻,安全性高,因而是一种有效科学、安全理想的治疗方法。
Objective: To observe and analyze the clinical efficacy of valsartan combined with nifedipine GITS in the diagnosis and treatment of essential hypertension. Methods: 77 patients with essential hypertension treated in our hospital from April 2014 to April 2015 according to the voluntary principle of patients were divided into groups. Namely, the control group of 35 cases, given conventional methods of treatment; observation group of 42 patients were given valsartan combined with nifedipine controlled release tablets. Analysis and comparison of clinical diagnosis and treatment of two groups of patients and efficacy. Results: After clinical treatment, the total effective rate of clinical diagnosis and treatment (97.62%) in the observation group was significantly higher than that in the control group (85.71%), with statistical significance (P <0.05). Adverse reactions in both groups (4.76%, 8.57%) were lower, and there was no statistical significance (P> 0.05). Conclusion: Valsartan combined with nifedipine controlled release tablets in patients with essential hypertension should be treated clinically. The treatment effect is light, the safety is high, and it is an effective and safe and ideal treatment.